Market Place
Sourcing Support
Remember that record biotech IPO party in 2018? no ‘happily ever after’
08 May 2023 //
ENDPTS
Aptinyx evaluates future of the company following two failed trials, 60% layoffs
31 Mar 2023 //
ENDPTS
Aptinyx Reports on 4Q and Full Year 2022 Results
30 Mar 2023 //
BUSINESSWIRE
Aptinyx dumps dementia drug, stops PTSD trial after phase 2 flop
28 Feb 2023 //
FIERCE BIOTECH
Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment
27 Feb 2023 //
BUSINESSWIRE
Aptinyx to Present at the SVB Securities Global Biopharma Conference
31 Jan 2023 //
BUSINESSWIRE
Preclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented
10 Nov 2022 //
BUSINESSWIRE
Drugs up for sale, on the shelf in biotech pipeline clear-outs
09 Nov 2022 //
FIERCEBIOTECH
Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights
08 Nov 2022 //
BUSINESSWIRE
Clinical Evaluation of Aptinyx`s NYX-783 to Be Funded by $5.6M NIH Grant
03 Nov 2022 //
BUSINESSWIRE
Aptinyx to Report Q3 2022 Financial Results on Tuesday, November 8, 2022
18 Oct 2022 //
BUSINESSWIRE
Aptinyx concludes subject enrolment in Phase II Parkinson’s trial
26 Aug 2022 //
CLINICALTRIALSARENA
Aptinyx Completes Enrollment in Phase 2 Study of NYX-458
25 Aug 2022 //
BUSINESSWIRE
The placebo caught up’:Months after diabetic nerve pain fail, Aptinyx trial fall
13 Aug 2022 //
ENDPTS
Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia
12 Aug 2022 //
BUSINESSWIRE
Aptinyx Reports Second Quarter 2022 Financial Results and Recent Highlights
04 Aug 2022 //
BUSINESSWIRE
Aptinyx to Report Q2 2022 Financial Results on Thursday, August 4, 2022
15 Jul 2022 //
BUSINESSWIRE
Aptinyx to Participate in H.C. Wainwright 1st Annual Mental Health Conference
22 Jun 2022 //
BUSINESSWIRE
Aptinyx to Participate in H.C. Wainwright Global Investment Conference
18 May 2022 //
BUSINESSWIRE
Aptinyx Announces Poster Presentation Highlighting Preclinical Data on NYX-783
17 May 2022 //
BUSINESSWIRE
Aptinyx Reports First Quarter 2022 Financial Results
12 May 2022 //
BUSINESSWIRE
Aptinyx Presents Preclinical Data on NYX-783 in Models of PTSD
29 Apr 2022 //
BUSINESSWIRE
Aptinyx to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
27 Apr 2022 //
BUSINESSWIRE
Aptinyx pauses phase 2 trial of higher dose PTSD med
21 Apr 2022 //
FIERCEBIOTECH
Aptinyx follows a painful setback with yet another PhII failure
08 Apr 2022 //
ENDPTS
Aptinyx Reports Results from Phase 2b Study of NYX-2925
07 Apr 2022 //
BUSINESSWIRE
Aptinyx Reports Fourth Quarter and Full Year 2021 Results and Highlights
23 Mar 2022 //
BUSINESSWIRE
Aptinyx to Report Q4 and Full Year 2021 Financial Results on March 23
09 Mar 2022 //
BUSINESSWIRE
Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Fibromyalgia
28 Feb 2022 //
BUSINESSWIRE
Aptinyx Hosts Virtual Portfolio Review Event for NYX-2925 in Chronic Pain
09 Feb 2022 //
BUSINESSWIRE
Aptinyx to Present at the SVB Leerink 11th Annual Global Healthcare Conference
08 Feb 2022 //
BUSINESSWIRE
Aptinyx Announces Formation of Scientific Advisory Board
03 Feb 2022 //
BUSINESSWIRE
Aptinyx Highlights Key Goals and Anticipated Development Milestones for 2022
06 Jan 2022 //
BUSINESSWIRE
Aptinyx Initiates Phase 2b Study of NYX-783 in PTSD
16 Dec 2021 //
BUSINESSWIRE
Aptinyx to Participate in Piper Sandler Virtual Healthcare Conference
18 Nov 2021 //
BUSINESSWIRE
Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925
27 Oct 2021 //
BUSINESSWIRE
Aptinyx Appoints Gilmore O’Neill to Board of Directors
20 Oct 2021 //
BUSINESSWIRE
Rosalind Franklin University Collaborates with Aptinyx
22 Sep 2021 //
PRNEWSWIRE
Aptinyx Secures $50M Growth Capital Credit Facility from K2 HealthVentures
16 Sep 2021 //
BUSINESSWIRE
Aptinyx to Participate in H.C. Wainwright Annual Global Investment Conference
31 Aug 2021 //
BUSINESSWIRE
CORRECTING and REPLACING Aptinyx Reports Second Quarter 2021 Financial Results
10 Aug 2021 //
BUSINESSWIRE
Aptinyx to Participate in 2021 Wedbush PacGrow Healthcare Virtual Conference
04 Aug 2021 //
BUSINESSWIRE
Aptinyx to Report Second Quarter 2021 Financial Results
26 Jul 2021 //
BUSINESSWIRE
Aptinyx to Participate in William Blair Biotech Focus Conference 2021
12 Jul 2021 //
BUSINESSWIRE
Aptinyx to Participate in Upcoming Investor Conferences
17 Jun 2021 //
BUSINESSWIRE
Aptinyx Provides Update on NYX-783 Development Program
16 Jun 2021 //
BUSINESSWIRE
Aptinyx to Participate in Upcoming Investor Conferences
16 Jun 2021 //
BUSINESSWIRE
Aptinyx Provides Update on NYX-783 Development Program
15 Jun 2021 //
BUSINESSWIRE
Aptinyx Announces Publication of Review Article Highlighting Preclinical Data
19 Jan 2021 //
BUSINESSWIRE
Aptinyx Announces Publication of Review Article Highlighting Preclinical Data
18 Jan 2021 //
BUSINESSWIRE
Aptinyx Announces Recommencement of Phase 2 Study of NYX-2925
04 Jan 2021 //
NEURO-CENTRAL
Aptinyx Announces Recommencement of Phase 2 Study of NYX-2925
04 Jan 2021 //
BUSINESSWIRE
Aptinyx Announces Pricing of Public Offering of Common Stock
10 Jan 2020 //
GLOBE NEWSWIRE
Matinas BioPharma Announces Proposed Public Offering of Common Stock
09 Jan 2020 //
GLOBE NEWSWIRE
Aptinyx`s lead drug makes cut in small fibromyalgia trial
11 Jun 2019 //
ENDPTS
Aptinyx Announces Closing of IPO & Full Exercise of Underwriters` Option
25 Jun 2018 //
PRESS RELEASE
Aptinyx Presents Data on NMDA Receptor Modulator NYX-458
15 Mar 2018 //
PRESS RELEASE
Aptinyx Presents Preclinical and Phase 1 Clinical Data on NYX-2925
08 Mar 2018 //
PRESS RELEASE
